Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
Sales estimated to double in 2019 and exceed EUR 50 million
Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.
GeoVax Labs, Inc. announced it has implemented a 1-for-500 reverse stock split of its common stock with a market effective date of May 2, 2019.
With revenue increase of 20 per cent in the first quarter we report all-time high net sales, first time over SEK 1.8 billion in a quarter.
The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys’s first quarter interim statement 2019 and provide an outlook for 2019.
Neos Therapeutics, Inc. announced that it will report its first quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, May 9, 2019.
MyoKardia, Inc. announced that it will report first quarter 2019 financial and operating results on Thursday, May 9, 2019.
Eisai Co., Ltd has bought out Purdue Pharma L.P.'s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer Disease.